Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

William McKean

Salt Lake City, UT Medical Doctor

NPI 1548624828 CMS profile 5313826

50 N Medical Dr, L4, Salt Lake City, UT 84132

Open in the dashboard

General payments

$2,378

43 records reported · program years 2023–2025

Research payments

$1,270

Paid to them · 2 records reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,359,388 paid to institutions, not to them · program years 2024–2025

Through program year 2025, William McKean of Salt Lake City, UT is reported in the CMS Open Payments database as having received $2,378 across 43 general payments and $1,270 in research payments paid to them. Separately, studies naming them as principal investigator received $3,359,388 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $900 29
2025 Research $1,270 2
2024 General $1,438 12
2023 General $40 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William McKean
  • Utah median
  • Middle half of Utah
  • National median

In program year 2025, general payments to William McKean were reported at $900. Among 8,686 Utah profiles paid that year, the median was $168 and the middle half received between $54 and $620.

Show as a table
Year William McKean Utah median Middle half National median
2019 $0 $144 $40–$609 $163
2020 $0 $101 $32–$405 $114
2021 $0 $137 $38–$522 $132
2022 $0 $149 $44–$534 $149
2023 $40 $159 $48–$566 $160
2024 $1,438 $163 $48–$591 $164
2025 $900 $168 $54–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Daiichi Sankyo Inc. $1,845 11 payments
  2. Merck Sharp & Dohme Corporation $99 5 payments
  3. Pfizer Inc. $97 9 payments
  4. EMD Serono, Inc. $62 2 payments
  5. Lilly USA, LLC $49 3 payments
  6. Genmab U.S., Inc. $36 2 payments
  7. BeiGene USA, Inc. $32 1 payment
  8. Novartis Pharmaceuticals Corporation $27 1 payment
  9. Genentech USA, Inc. $26 1 payment
  10. AbbVie, Inc. $23 1 payment
  11. Other $82 7 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Consulting Fee $1,698 3 payments
  2. Food and Beverage $680 40 payments
Products named General payments · program years 2023–2025
  1. Datroway $485 1 payment
  2. ENHERTU $147 8 payments
  3. KEYTRUDA $99 5 payments
  4. Padcev $57 7 payments
  5. VERZENIO $49 3 payments
  6. RETEVMO $49 3 payments
  7. JAYPIRCA $49 3 payments
  8. TIVDAK $36 2 payments
  9. LYNPARZA $34 2 payments
  10. WELIREG $33 2 payments
  11. Other $470 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2023–2025
  1. Pfizer Inc. $1,270 2 payments

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$11,883

Of which drugs: $2,010

Medicare patients

39

Average age 71

Services billed

2,374

23 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Cancer 54%
Diabetes 33%
Alzheimer's or dementia 0%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, palonosetron hcl, 25 mcg J2469 Office 11 220 $181
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 205 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $71
$71 — —
VERZENIO
  • Lilly USA, LLC $16
$16 — —
RETEVMO
  • Lilly USA, LLC $16
$16 — —
JAYPIRCA
  • Lilly USA, LLC $16
$16 — —
LUNSUMIO
  • Genentech USA, Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record